Mar 22nd 2013 - Edison Investment Research today published a report on TiGenix entitled "Spain Signs Up". In summary, the report says:
TiGenix has achieved a major goal by getting a major EU state, Spain, to agree full reimbursement for ChondroCelect. Revenues for units sold in 2012 were €3.4m. An additional €0.7m (carried over form 2011) took the total to total €4.1m. In 2013, management guidance indicates about €6m of sales assuming Spanish French sales. The Cx611 rheumatoid arthritis Phase IIa trial reports in Q213. An autoimmune indication will be selected for further development if efficacy is seen. Deals on Cx601 may occur in 2013; the Phase III for perianal fistula closure is due to complete in H2-2014 with a 2015 filing planned.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
